Cargando…

Envelope Glycoprotein based multi-epitope vaccine against a co-infection of Human Herpesvirus 5 and Human Herpesvirus 6 using in silico strategies

The Human Betaherpesviruses HHV-5 and HHV-6 are quite inimical in immunocompromised hosts individually. A co-infection of both has been surmised to be far more disastrous. This can be attributed to a synergetic effect of their combined pathologies. While there have been attempts to develop a vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Gandhamaneni, Bharath Sai, Krishnamoorthy, HemaNandini Rajendran, Veerappapillai, Shanthi, Mohapatra, Soumya R., Karuppasamy, Ramanathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557995/
https://www.ncbi.nlm.nih.gov/pubmed/36227524
http://dx.doi.org/10.1007/s10719-022-10083-7
_version_ 1784807351655596032
author Gandhamaneni, Bharath Sai
Krishnamoorthy, HemaNandini Rajendran
Veerappapillai, Shanthi
Mohapatra, Soumya R.
Karuppasamy, Ramanathan
author_facet Gandhamaneni, Bharath Sai
Krishnamoorthy, HemaNandini Rajendran
Veerappapillai, Shanthi
Mohapatra, Soumya R.
Karuppasamy, Ramanathan
author_sort Gandhamaneni, Bharath Sai
collection PubMed
description The Human Betaherpesviruses HHV-5 and HHV-6 are quite inimical in immunocompromised hosts individually. A co-infection of both has been surmised to be far more disastrous. This can be attributed to a synergetic effect of their combined pathologies. While there have been attempts to develop a vaccine against each virus, no efforts were made to contrive an effective prophylaxis for the highly detrimental co-infection. In this study, an ensemble of viral envelope glycoproteins from both the viruses was utilized to design a multi-epitope vaccine using immunoinformatics tools. A collection of bacterial protein toll-like receptor agonists (BPTAs) was screened to identify a highly immunogenic adjuvant for the vaccine construct. The constructed vaccine was analysed using an array of methodologies ranging from World population coverage analysis to Immune simulation, whose results indicate high vaccine efficacy and stability. Furthermore, codon optimization and in silico cloning analysis were performed to check for efficient expression in a bacterial system. Collectively, these findings demonstrate the potential of the constructed vaccine to elicit an immune response against HHV-5 and HHV-6, thus supporting the viability of in vitro and in vivo studies.
format Online
Article
Text
id pubmed-9557995
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-95579952022-10-13 Envelope Glycoprotein based multi-epitope vaccine against a co-infection of Human Herpesvirus 5 and Human Herpesvirus 6 using in silico strategies Gandhamaneni, Bharath Sai Krishnamoorthy, HemaNandini Rajendran Veerappapillai, Shanthi Mohapatra, Soumya R. Karuppasamy, Ramanathan Glycoconj J Original Article The Human Betaherpesviruses HHV-5 and HHV-6 are quite inimical in immunocompromised hosts individually. A co-infection of both has been surmised to be far more disastrous. This can be attributed to a synergetic effect of their combined pathologies. While there have been attempts to develop a vaccine against each virus, no efforts were made to contrive an effective prophylaxis for the highly detrimental co-infection. In this study, an ensemble of viral envelope glycoproteins from both the viruses was utilized to design a multi-epitope vaccine using immunoinformatics tools. A collection of bacterial protein toll-like receptor agonists (BPTAs) was screened to identify a highly immunogenic adjuvant for the vaccine construct. The constructed vaccine was analysed using an array of methodologies ranging from World population coverage analysis to Immune simulation, whose results indicate high vaccine efficacy and stability. Furthermore, codon optimization and in silico cloning analysis were performed to check for efficient expression in a bacterial system. Collectively, these findings demonstrate the potential of the constructed vaccine to elicit an immune response against HHV-5 and HHV-6, thus supporting the viability of in vitro and in vivo studies. Springer US 2022-10-13 2022 /pmc/articles/PMC9557995/ /pubmed/36227524 http://dx.doi.org/10.1007/s10719-022-10083-7 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Gandhamaneni, Bharath Sai
Krishnamoorthy, HemaNandini Rajendran
Veerappapillai, Shanthi
Mohapatra, Soumya R.
Karuppasamy, Ramanathan
Envelope Glycoprotein based multi-epitope vaccine against a co-infection of Human Herpesvirus 5 and Human Herpesvirus 6 using in silico strategies
title Envelope Glycoprotein based multi-epitope vaccine against a co-infection of Human Herpesvirus 5 and Human Herpesvirus 6 using in silico strategies
title_full Envelope Glycoprotein based multi-epitope vaccine against a co-infection of Human Herpesvirus 5 and Human Herpesvirus 6 using in silico strategies
title_fullStr Envelope Glycoprotein based multi-epitope vaccine against a co-infection of Human Herpesvirus 5 and Human Herpesvirus 6 using in silico strategies
title_full_unstemmed Envelope Glycoprotein based multi-epitope vaccine against a co-infection of Human Herpesvirus 5 and Human Herpesvirus 6 using in silico strategies
title_short Envelope Glycoprotein based multi-epitope vaccine against a co-infection of Human Herpesvirus 5 and Human Herpesvirus 6 using in silico strategies
title_sort envelope glycoprotein based multi-epitope vaccine against a co-infection of human herpesvirus 5 and human herpesvirus 6 using in silico strategies
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9557995/
https://www.ncbi.nlm.nih.gov/pubmed/36227524
http://dx.doi.org/10.1007/s10719-022-10083-7
work_keys_str_mv AT gandhamanenibharathsai envelopeglycoproteinbasedmultiepitopevaccineagainstacoinfectionofhumanherpesvirus5andhumanherpesvirus6usinginsilicostrategies
AT krishnamoorthyhemanandinirajendran envelopeglycoproteinbasedmultiepitopevaccineagainstacoinfectionofhumanherpesvirus5andhumanherpesvirus6usinginsilicostrategies
AT veerappapillaishanthi envelopeglycoproteinbasedmultiepitopevaccineagainstacoinfectionofhumanherpesvirus5andhumanherpesvirus6usinginsilicostrategies
AT mohapatrasoumyar envelopeglycoproteinbasedmultiepitopevaccineagainstacoinfectionofhumanherpesvirus5andhumanherpesvirus6usinginsilicostrategies
AT karuppasamyramanathan envelopeglycoproteinbasedmultiepitopevaccineagainstacoinfectionofhumanherpesvirus5andhumanherpesvirus6usinginsilicostrategies